


What is claimed is:

1. A compound of Formula (I):



Formula (I)

wherein:

- 5 B is heteroarylene; wherein heteroarylene is selected from an aromatic monocyclic ring having five members of which at least one member is a N, O or S atom and which optionally contains one additional N atom;

A and E are independently phenylene or pyridinylene;

t is an integer from 1 to 4;

- 10 R₁ is selected from hydrogen, C₁₋₈alkyl, C₁₋₈alkoxy, NH₂, NH(C₁₋₈alkyl), N(C₁₋₈alkyl)₂, halogen or hydroxy; wherein R₁ is substituted on the 3, 4 or 5 position of the "A" ring;

R₂ and R₃ are independently selected from hydrogen, C₁₋₈alkyl-R₄ or C₃₋₆cycloalkyl;

- 15 R₄ is selected from (C₁₋₈)alkoxy, NH₂, NH(C₁₋₈alkyl), N(C₁₋₈alkyl)₂, (halo)₁₋₃, hydroxy, C₃₋₆cycloalkyl-R₅, heterocyclyl-R₅, aryl-R₅ or heteroaryl-R₅; and,


R₅ is 1 to 2 substituents selected from hydrogen, C₁₋₈alkyl or (C₁₋₈)alkoxy (wherein alkoxy is substituted on a carbon atom);

and pharmaceutically acceptable salts thereof.

2. The compound of claim 1 wherein B is selected from oxazolylenes, thiazolylenes, imidazolylenes, pyrimidinyls, pyrazinyls or triazinyls.
3. The compound of claim 1 wherein B is selected from oxazolylenes, thiazolylenes or imidazolylenes.
- 5 4. The compound of claim 1 wherein t is an integer from 1 to 2.
5. The compound of claim 1 wherein t is an integer 1.
6. The compound of claim 1 wherein R₁ is selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, NH₂, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, halogen or hydroxy; wherein R₁ is substituted on the 3, 4 or 5 position of the "A" ring.
- 10 7. The compound of claim 1 wherein R₁ is selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy or halogen; wherein R₁ is substituted on the 4 position of the "A" ring.
8. The compound of claim 1 wherein R₂ and R₃ are independently selected from hydrogen, C₁₋₄alkyl-R₄ or C₃₋₆cycloalkyl.
- 15 9. The compound of claim 1 wherein R₄ is selected from C₁₋₄alkoxy, NH₂, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, (halo)₁₋₃, hydroxy, C₃₋₆cycloalkyl-R₅, heterocyclyl-R₅, aryl-R₅ or heteroaryl-R₅.
10. The compound of claim 1 wherein R₄ is selected from heterocyclyl-R₅ or heteroaryl-R₅.
- 20 11. The compound of claim 1 wherein R₄ is selected from pyrrolidinyl-R₅, morpholinyl-R₅, furyl-R₅ or indolyl-R₅.

12. The compound of claim 1 wherein R_5 is 1 to 2 substituents selected from hydrogen, C_{1-4} alkyl or (C_{1-4}) alkoxy (wherein alkoxy is substituted on a carbon atom).
13. The compound of claim 1 wherein the compound of Formula (I) is selected from a compound of Formula (Ia):

5



Formula (Ia)

wherein R_1 , position "a" and R_3 are dependently selected from:

R_1	a		R_3
Cl,	3	and	n-propyl;
Cl,	4	and	n-propyl;
Cl,	3	and	isobutyl;
Cl,	3	and	cyclopentyl;
Cl,	3	and	cyclohexyl;
Cl,	3	and	cyclopropyl;
Cl,	3	and	CH_2 -(1-Me)-2-pyrrolidinyl;
Cl,	3	and	$(CH_2)_2$ -4-morpholinyl;
Cl,	3	and	(5-Me)furfuryl;
Cl,	3	and	$(CH_2)_2$ -(5-OMe)-1 <i>H</i> -indol-3-yl;
Cl,	4	and	cyclopentyl;
or			
Cl,	3	and	H.

14. A method for treating or ameliorating a reactive oxygen species mediated inflammatory disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of claim

PRD0017

1.

15. The method of claim 14 wherein the reactive oxygen species is selected from a superoxide, hydrogen peroxide, hydroxyl radical or HOCl reactive oxygen species.
- 5 16. The method of claim 14 wherein the reactive oxygen species mediated inflammatory disorder is selected from a phosphorylation mediated disorder, a polymorphonuclear leucocyte mediated disorder, a macrophage mediated disorder, a lipopolysaccharide mediated disorder, a tumor necrosis factor- α mediated disorder, a cytokine IFN- γ mediated disorder, an
10 interleukin-2 mediated disorder, inflammatory arthritis, potassium peroxochromate arthritis, rheumatoid arthritis, osteoarthritis or Alzheimer's disease.
17. The method of claim 14 wherein the therapeutically effective amount of the compound of claim 1 is from about 0.001 mg/kg/day to about 1000
15 mg/kg/day.